A review of the pharmacokinetics, pharmacodynamics, efficacy, and safety of direct oral anticoagulants in patients undergoing bariatric surgery [0.03%]
口服直接抗凝药物的药代动力学、药效学及其在代谢手术患者中的有效性和安全性的系统评价和 meta 分析
Dino Kröll,Guido Stirnimann,Dereck Wentworth
Dino Kröll
The role of direct oral anticoagulants for prevention of venous thromboembolism (VTE) in bariatric surgery has been unclear. Current clinical guidelines recommend against using direct oral anticoagulants in bariatric surgery but lack the in...
Risks of anticoagulation discontinuation after first venous thromboembolism in inherited thrombophilia: a long-term cohort study [0.03%]
遗传性血栓形成倾向患者首次发生静脉血栓栓塞后抗凝停药的风险：一项长期队列研究
Sang-A Kim,Sin Young Park,Ji Yun Lee et al.
Sang-A Kim et al.
Background: Inherited thrombophilia confers high venous thromboembolism (VTE) recurrence risk, and guidelines generally recommend indefinite anticoagulation after first VTE. However, long-term data comparing outcomes betw...
Corrigendum to 'Platelet dense granule defect: experience in the French population' [Research and Practice in Thrombosis and Haemostasis Volume 10, Issue 2, February 2026, 103364] [0.03%]
关于“血小板致密颗粒缺陷：法国人群中的经验”一文的勘误(发表于《血栓与止血研究与实践》2026年，第10卷，第2期，103364页)
Delphine Borgel,Agathe Beauvais,Cécile Bally et al.
Delphine Borgel et al.
[This corrects the article DOI: 10.1016/j.rpth.2026.103364.]. © 2026 The Author(s).
Assessing the efficacy of a single-cycle measurement and adjustment strategy for direct oral anticoagulants in frail older patients: rationale and design of the DOAC-FRAIL randomized controlled trial [0.03%]
脆弱老年患者直接口服抗凝剂单一周期测量和调整策略有效性的评价：DOAC-FRAIL随机对照试验的方案和设计合理性评估
Fabienne J H Magdelijns,Melanie J de Jong,Kristien Winckers et al.
Fabienne J H Magdelijns et al.
Background: Frail older patients are at high risk of both thromboembolism and bleeding, making anticoagulant therapy challenging. Direct oral anticoagulants (DOACs) have largely replaced vitamin K antagonists because of c...
Randomized Controlled Trial
Research and practice in thrombosis and haemostasis. 2026 Jun 17;10(4):106800. DOI:10.1016/j.rpth.2026.106800 2026
International collaborative study for the calibration of a proposed World Health Organization International Standard for thromboplastin, human, recombinant: a report from the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)-Scientific and Standardization Committee (SSC)/ISTH working group on prothrombin time/international no [0.03%]
国际协作研究校准拟议的世界卫生组织国际标准血浆衍生凝血酶原浓缩剂：国际临床化学和实验室医学联合会（ifcc）/科学与标准委员会（ssc）/ishemophilia协会(protime/international normalized ratio)工作组报告
Michelle P van der Helm,Claudia J J van Rijn,Shanti S Baktawar et al.
Michelle P van der Helm et al.
Background: The availability of International Reference Preparations for thromboplastins, later on referred to as International Standards (ISs) for thromboplastins is essential for calibration of prothrombin time (PT) mea...
Safety of von Willebrand factor substitution for neuraxial anesthesia in women with persistent von Willebrand deficiency at delivery [0.03%]
有关分娩女性持久性血管性血友病因子缺陷行神经轴阻滞麻醉安全性的研究
Yaquine Mechelfekh,Sarah Guérin,Kenza Kali et al.
Yaquine Mechelfekh et al.
Background: Neuraxial anesthesia (NA) constitutes a risk for patients with bleeding disorders, the main hemorrhagic adverse effect being spinal epidural hematoma. No clear recommendation has been issued concerning NA use ...
Outcomes in venous thromboembolism with retained vs removed inferior vena cava filters: an analysis from the Registro Informatizado de Enfermedad TromboEmbólica [0.03%]
下腔静脉滤器置入后取出与未取出对比的肺血栓栓塞症预后的差异：来自Registro Informatizado de Enfermedad TromboEmbólica数据库的分析
Omri Cohen,Davide Santagata,Gili Kenet et al.
Omri Cohen et al.
Background: Retrievable inferior vena cava (IVC) filters are used in patients with acute venous thromboembolism (VTE) who have temporary contraindications to anticoagulation. Although guidelines recommend removing filters...
Efficacy and safety of recombinant activated factor VII for secondary prophylaxis in patients with Glanzmann thrombasthenia [0.03%]
用于Glanzmann血小板功能异常症二级预防的重组活化因子VII疗效及安全性
Pablo García-Jaén,Nuria Fernández-Mosteirin,María Luisa Serrano et al.
Pablo García-Jaén et al.
Background: Glanzmann thrombasthenia (GT) is a rare inherited platelet disorder associated with recurrent and sometimes life-threatening bleeding. Recombinant activated factor VII (rFVIIa) is approved for treatment of ble...
Should we focus on sustainable thromboprophylaxis and avoid overuse of low-molecular-weight heparins? [0.03%]
我们应该关注可持续的抗凝治疗并避免过量使用低分子肝素吗？
Gerard Gurumurthy,Bingwen Eugene Fan,Juditha Gurumurthy et al.
Gerard Gurumurthy et al.
Low-molecular-weight heparins (LMWHs) have become a near-routine prescription for venous thromboembolism (VTE) prevention in hospitalized patients in several parts of the world. Their use may be reinforced by embedded order sets and 'opt-ou...
Immunopeptidomics of blood coagulation factor IX: a core peptide derived from the protease domain is promiscuously presented on HLA-DR [0.03%]
关于血液凝固因子IX的免疫肽组学：由蛋白酶结构域衍生的核心肽以多面性方式呈现于HLA-DR上
Michela Leoni,Margot Dierickx,Mariarosaria Miranda et al.
Michela Leoni et al.
Background: Hemophilia B is an X-linked bleeding disorder that results in a qualitative or quantitative factor IX (FIX) deficiency. A subset of hemophilia B patients treated with FIX replacement therapy develop antibodies...